Sylvia Gutierrez, MD
Family Medicine · Phoenix, AZNPI 1023103264
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,190 of the $3,407 with a category attached, or 64.3%. 9 manufacturers reported payments, led by GSK at 53.4% of the total. Reporting peaked in 2019 at $3,176 and has fallen 96.6% since, to $108 in 2024.
Across 31 payments — averaging $109.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Pfizer$1K
- Lilly USA, LLC$50
- Abbott$49
- Currax Pharmaceuticals LLC$38
- Novo Nordisk$36
- plus $72 from 3 others
Across 80 payments — averaging $4404.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$198K
- GSK$118K
- Sanofi Pasteur Inc.$37K
What the payments were for
- Travel & lodging$2,19064%
- Food & beverage$1,19235%
- Education$251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $1,821 |
| Pfizer | 4 | $1,341 |
| Lilly USA, LLC | 3 | $50 |
| Abbott | 2 | $49 |
| Currax Pharmaceuticals LLC | 2 | $38 |
| Novo Nordisk | 2 | $36 |
| Boehringer Ingelheim | 2 | $30 |
| Astellas Pharma US Inc | 1 | $29 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR - 13$1,341
How this compares
$3,407 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $39,502 |
| OzempicSemaglutide | 36 | $34,050 |
| RybelsusSemaglutide | 15 | $24,384 |
| JanuviaSitagliptin Phosphate | 19 | $17,438 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $11,078 |
| Atorvastatin Calcium | 199 | $1,408 |
| Gabapentin | 55 | $1,357 |
| Metformin Hcl | 178 | $1,231 |
| Levothyroxine Sodium | 140 | $1,074 |
| Lisinopril | 152 | $1,060 |
| Ibuprofen | 53 | $967 |
| Metoprolol Succinate | 63 | $889 |
| Ibandronate Sodium | 28 | $886 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $877 |
| Rosuvastatin Calcium | 93 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $36 | $58,43451 claims |
| Boehringer IngelheimJardiance | $30 | $39,50227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Randy GelowPhoenix$56K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.